|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
With the exception of rs3803662 (TOX3), there was no evidence that any of the SNPs associated with BC susceptibility were associated with the BC survival.
|
22532573 |
2012 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
We confirmed associations between rs13387042 (2q35), rs4973768 (SLC4A7), rs10941679 (5p12), rs2981582 (FGFR2), rs3817198 (LSP1), rs3803662 (TOX3), and rs6504950 (STXBP4) with breast cancer.
|
23893088 |
2013 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
We conclude that SNP rs3803662 is a putative risk factor for breast cancer in Chinese Han women.
|
24446301 |
2014 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Two SNPs consistently associated with breast cancer: approximately 25% of individuals of European descent are homozygous for allele A of rs13387042 on chromosome 2q35 and have an estimated 1.44-fold greater risk than noncarriers, and for allele T of rs3803662 on 16q12, about 7% are homozygous and have a 1.64-fold greater risk.
|
17529974 |
2007 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Two index SNPs were associated with breast cancer: rs3803662 at 16q12.2/TOX3 (Hazard ratio [HR] for the T allele = 0.79, 95% CI: 0.67-0.92, P = 0.003) and rs10941679 at 5p12 (HR for the G allele = 1.31, 95% CI: 1.06-1.63, P = 0.014).
|
21795501 |
2011 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
TOX3-rs3803662, may confer some degrees of risk of breast cancer in Iranian population.
|
30515698 |
2019 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Three SNPs were significantly associated with a breast cancer risk in multivariate analysis: rs2046210 (per allele OR=1.37 [95% CI: 1.11-1.70]), rs3757318 (OR=1.33[1.05-1.69]), and rs3803662 (OR=1.28 [1.07-1.55]).
|
24289300 |
2013 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
This meta-analysis suggested that TOX3 rs3803662 polymorphism was associated with increased breast cancer risk.
|
29578175 |
2018 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
These results indicate an additive effect of the TOX3 rs3803662 and 2q35 rs13387042 alleles for BC risk.
|
24532140 |
2014 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The TNRC9 rs3803662 C>T polymorphism is greatly related to increased risk of BC, in both Asian and Caucasian populations.
|
27525937 |
2016 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The results suggest that the effect of the risk allele of rs3803662 is strongest in luminal A tumours and that the expression levels of TOX3 and/or LOC643714 affect the progression of breast cancer.
|
23270421 |
2012 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The present meta-analysis suggests that rs3803662 polymorphism is significantly associated with breast cancer risk in Caucasian women, and we did not find the association in Asian women.
|
27350156 |
2016 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The most strongly associated SNP was in intron 2 of the FGFR2 gene that is amplified and overexpressed in 5-10% of BC. rs3803662 of TNRC9 gene has been shown to be the SNP with the strongest association with BC, in particular, this polymorphism seems to be correlated with bone metastases and estrogen receptor positivity.
|
21996731 |
2012 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The minor alleles of SNP rs2981582 and rs889312 were each associated with increased breast cancer risk in BRCA2 mutation carriers (per-allele hazard ratio [HR] = 1.32, 95% CI: 1.20-1.45, p(trend) = 1.7 x 10(-8) and HR = 1.12, 95% CI: 1.02-1.24, p(trend) = 0.02) but not in BRCA1 carriers. rs3803662 was associated with increased breast cancer risk in both BRCA1 and BRCA2 mutation carriers (per-allele HR = 1.13, 95% CI: 1.06-1.20, p(trend) = 5 x 10(-5) in BRCA1 and BRCA2 combined).
|
18355772 |
2008 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The known breast cancer SNPs rs13281615, rs2981582 and rs3803662 were confirmed as associated with breast cancer risk (P (allelic test) = 1.8 x 10(-2), OR = 1.17; P (allelic test) = 2.2 x 10(-3), OR = 1.22; P (allelic test) = 5.1 x 10(-2), OR = 1.15, respectively) in the West of Ireland cohort.
|
19005751 |
2009 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The rs3803662 single nucleotide polymorphism (SNP) in the TOX3/LOC643714 region was identified as a breast cancer susceptibility genetic variant in recent genome-wide association studies of women of European ancestry and has been replicated in other populations of European ancestry.
|
20406955 |
2010 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Ten of the 11 breast cancer susceptibility loci reported by consortia also showed associations in our predominantly Caucasian study population, and the associations were independent of BMI; four FGFR2 SNPs and TNRC9-rs3803662 were among the most notable associations.
|
23717390 |
2013 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Subjects carrying an allele of rs2981582 had reduced breast cancer risk (GA vs GG: OR=0.444, 95% CI=0.262-0.752; AA vs GG: OR=0.579, 95% CI=0.342-0.983). rs3803662 and rs3817198 SNPs did not significantly differ between cases and controls (P=0.408 and 0.116, respectively).
|
26911390 |
2016 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
SNP rs3803662 (TOX3/TNRC9) is an independent prognostic factor for breast cancer in Henan Han Population.
|
31317673 |
2019 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Significant associations with BC were observed for rs3803662 (dominant comparison: OR, 0.89; 95% CI, 0.84-0.95; P = .0008; recessive comparison: OR, 1.17; 95% CI, 1.07-1.28; P = .0004; over-dominant comparison: OR, 1.07; 95% CI, 1.02-1.11; P = .002; allele comparison: OR, 0.90; 95% CI, 0.86-0.95; P = .0002), rs8051542 (dominant comparison: OR, 0.87; 95% CI, 0.83-0.91; P < .0001; recessive comparison: OR, 1.19; 95% CI, 1.11-1.28; P < .0001; over-dominant comparison: OR, 1.07; 95% CI, 1.02-1.11; P = .004; allele comparison: OR, 0.89; 95% CI, 0.86-0.91; P < .0001), and rs12922061 (dominant comparison: OR, 0.83; 95% CI, 0.73-0.93; P = .002; over-dominant comparison: OR, 1.43; 95% CI, 1.27-1.61; P < .0001) polymorphisms in the overall population.
|
31324582 |
2019 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Recently, genetic polymorphism (rs3803662C>T) in TOX3 was reported to induce the risk of breast cancer.
|
24069142 |
2013 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Odds ratios for breast cancer were greatest for FGFR2-rs2981582 and TNRC9-rs3803662 and, for these 2 SNPs, were significantly greater for estrogen receptor (ER)-positive than for ER-negative disease, both in our data and in meta-analyses of all published data (pooled per-allele ORs [95% confidence intervals] for ER-positive vs ER-negative disease: 1.30 [1.26-1.33] vs 1.05 [1.01-1.10] for FGFR2; interaction P < .001; and 1.24 [1.21-1.28] vs 1.12 [1.07-1.17] for TNRC9; interaction P < .001).
|
20664043 |
2010 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
None of the three polymorphisms was significantly associated with breast cancer risk in the whole data set (P = 0.151, 0.644, and 0.737 for rs3803662, rs12443621. and rs8051542, respectively).
|
20213080 |
2010 |
|
rs3803662
|
|
Breast Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
No statistically significant association was found between the rs3803662 polymorphism and breast cancer in patients or healthy controls.
|
29683073 |
2018 |
|
rs3803662
|
|
Breast Carcinoma
|
A |
0.900 |
GeneticVariation
|
GWASCAT |
Large-scale genotyping identifies 41 new loci associated with breast cancer risk.
|
23535729 |
2013 |